Skip to main content
Top
Published in: International Journal of Clinical Oncology 5/2016

01-10-2016 | Original Article

Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy

Authors: Hiromitsu Kanzaki, Masaaki Kataoka, Atsushi Nishikawa, Kotaro Uwatsu, Kei Nagasaki, Noriko Nishijima, Takashi Ochi, Teruhito Mochizuki

Published in: International Journal of Clinical Oncology | Issue 5/2016

Login to get access

Abstract

Background

We retrospectively investigated the impact on survival of early tumor reduction during definitive radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC) patients, according to their histological subtypes.

Methods

Between November 2006 and December 2012, 152 consecutive patients with inoperable stage III NSCLC who underwent definitive radiotherapy were reviewed retrospectively. Forty-one patients were excluded for not satisfying the inclusion criteria. Forty-five (40.5 %) and 48 (43.2 %) patients were diagnosed with squamous cell carcinoma (SQC) and adenocarcinoma (ADC), respectively. The tumor reduction rate (TRR) was defined as follows: TRR = 1−[gross tumor volume (GTV) on computed tomography at shrinking irradiation field planning]/(GTV on computed tomography at the initial treatment planning). The Cox proportional hazard model was used to identify significant prognostic factors for overall survival (OS) and progression-free survival (PFS).

Results

We evaluated 111 patients, with a median follow-up time of 52.2 months in surviving patients. The median TRR was 45.9 %. In all patients, there were significant associations between TRR and PFS (P = 0.036) on multivariate analysis, although TRR had no correlation with OS (P = 0.141). With respect to histological subtype, multivariate analyses revealed that a higher TRR showed significant associations with better OS and PFS in the SQC group (P = 0.013 and 0.040, respectively). In contrast, a higher TRR was associated with poorer OS in the ADC group (P = 0.030); there was no association between TRR and PFS.

Conclusion

We found that a higher TRR is a promising prognostic factor for better survival and disease control in SQC patients.
Literature
2.
go back to reference Reck M, Popat S, Reinmuth N et al (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii27–iii39CrossRefPubMed Reck M, Popat S, Reinmuth N et al (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii27–iii39CrossRefPubMed
3.
go back to reference D’Addario G, Früh M, Reck M et al (2010) Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v116–v119CrossRefPubMed D’Addario G, Früh M, Reck M et al (2010) Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v116–v119CrossRefPubMed
4.
go back to reference Dehing-Oberije C, Yu S, De Ruysscher D et al (2009) Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 74:355–362CrossRefPubMed Dehing-Oberije C, Yu S, De Ruysscher D et al (2009) Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 74:355–362CrossRefPubMed
5.
go back to reference Topkan E, Parlak C, Selek U (2013) Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients. Int J Radiat Oncol Biol Phys 87:697–704CrossRefPubMed Topkan E, Parlak C, Selek U (2013) Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients. Int J Radiat Oncol Biol Phys 87:697–704CrossRefPubMed
6.
go back to reference Sause W, Kolesar P, Taylor S IV et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364CrossRefPubMed Sause W, Kolesar P, Taylor S IV et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364CrossRefPubMed
7.
go back to reference Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699PubMed Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699PubMed
8.
go back to reference Machtay M, Hsu C, Komaki R et al (2005) Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 63:667–671CrossRefPubMed Machtay M, Hsu C, Komaki R et al (2005) Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 63:667–671CrossRefPubMed
9.
go back to reference Dehing-Oberije C, Aerts H, Yu S et al (2011) Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 81:360–368CrossRefPubMed Dehing-Oberije C, Aerts H, Yu S et al (2011) Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 81:360–368CrossRefPubMed
10.
go back to reference Alexander BM, Othus M, Caglar HB et al (2011) Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 79:1381–1387CrossRefPubMed Alexander BM, Othus M, Caglar HB et al (2011) Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 79:1381–1387CrossRefPubMed
11.
go back to reference Bradley JD, Ieumwananonthachai N, Purdy JA et al (2002) Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52:49–57CrossRefPubMed Bradley JD, Ieumwananonthachai N, Purdy JA et al (2002) Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52:49–57CrossRefPubMed
12.
go back to reference Werner-Wasik M, Swann RS, Bradley J et al (2008) Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I–II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:385–390CrossRefPubMed Werner-Wasik M, Swann RS, Bradley J et al (2008) Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I–II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:385–390CrossRefPubMed
13.
go back to reference Etiz D, Marks LB, Zhou SM et al (2002) Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 53:835–846CrossRefPubMed Etiz D, Marks LB, Zhou SM et al (2002) Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 53:835–846CrossRefPubMed
14.
go back to reference Zhao L, West BT, Hayman JA et al (2007) High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 68:103–110CrossRefPubMed Zhao L, West BT, Hayman JA et al (2007) High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 68:103–110CrossRefPubMed
15.
go back to reference Basaki K, Abe Y, Aoki M et al (2006) Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 64:449–454CrossRefPubMed Basaki K, Abe Y, Aoki M et al (2006) Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 64:449–454CrossRefPubMed
16.
go back to reference Koo TR, Moon SH, Lim YJ et al (2014) The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiat Oncol 9:283CrossRefPubMedPubMedCentral Koo TR, Moon SH, Lim YJ et al (2014) The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiat Oncol 9:283CrossRefPubMedPubMedCentral
17.
go back to reference Jabbour SK, Kim S, Haider SA et al (2015) Reduction in tumor volume by cone beam computed tomography predicts overall survival in non-small cell lung cancer treated with chemoradiation therapy. Int J Radiat Oncol Biol Phys 92:627–633CrossRefPubMed Jabbour SK, Kim S, Haider SA et al (2015) Reduction in tumor volume by cone beam computed tomography predicts overall survival in non-small cell lung cancer treated with chemoradiation therapy. Int J Radiat Oncol Biol Phys 92:627–633CrossRefPubMed
18.
go back to reference Brink C, Bernchou U, Bertelsen A et al (2014) Locoregional control of non-small cell lung cancer in relation to automated early assessment of tumor regression on cone beam computed tomography. Int J Radiat Oncol Biol Phys 89:916–923CrossRefPubMed Brink C, Bernchou U, Bertelsen A et al (2014) Locoregional control of non-small cell lung cancer in relation to automated early assessment of tumor regression on cone beam computed tomography. Int J Radiat Oncol Biol Phys 89:916–923CrossRefPubMed
19.
go back to reference Holgersson G, Bergström S, Bergqvist M et al (2011) Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer. Eur J Cancer 47:2415–2421CrossRefPubMed Holgersson G, Bergström S, Bergqvist M et al (2011) Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer. Eur J Cancer 47:2415–2421CrossRefPubMed
20.
go back to reference Nakayama Y, Hayakawa K, Mitsuhashi N et al (1997) Long-term survivors of non-small cell lung cancer after radiation therapy: the significance of histological type. Anticancer Res 17:2769–2773PubMed Nakayama Y, Hayakawa K, Mitsuhashi N et al (1997) Long-term survivors of non-small cell lung cancer after radiation therapy: the significance of histological type. Anticancer Res 17:2769–2773PubMed
21.
go back to reference Langer CJ, Besse B, Gualberto A et al (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28:5311–5320CrossRefPubMed Langer CJ, Besse B, Gualberto A et al (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28:5311–5320CrossRefPubMed
22.
go back to reference Miyakawa A, Shibamoto Y, Kosaki K et al (2013) Early response and local control of stage I non-small-cell lung cancer after stereotactic radiotherapy: difference by histology. Cancer Sci 104:130–134CrossRefPubMed Miyakawa A, Shibamoto Y, Kosaki K et al (2013) Early response and local control of stage I non-small-cell lung cancer after stereotactic radiotherapy: difference by histology. Cancer Sci 104:130–134CrossRefPubMed
23.
go back to reference Cox JD, Scott CB, Byhardt RW et al (1999) Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys 43:505–509CrossRefPubMed Cox JD, Scott CB, Byhardt RW et al (1999) Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys 43:505–509CrossRefPubMed
24.
go back to reference Hayakawa K, Mitsuhashi N, Saito Y et al (1996) Impact of tumor extent and location on treatment outcome in patients with stage III non-small cell lung cancer treated with radiation therapy. Jpn J Clin Oncol 26:221–228CrossRefPubMed Hayakawa K, Mitsuhashi N, Saito Y et al (1996) Impact of tumor extent and location on treatment outcome in patients with stage III non-small cell lung cancer treated with radiation therapy. Jpn J Clin Oncol 26:221–228CrossRefPubMed
25.
go back to reference Chapet O, Gerard JP, Riche B et al (2005) Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 63:1316–1324CrossRefPubMed Chapet O, Gerard JP, Riche B et al (2005) Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 63:1316–1324CrossRefPubMed
26.
go back to reference Yang SN, Liao CY, Chen SW et al (2011) Clinical implications of the tumor volume reduction rate in head-and-neck cancer during definitive intensity-modulated radiotherapy for organ preservation. Int J Radiat Oncol Biol Phys 79:1096–1103CrossRefPubMed Yang SN, Liao CY, Chen SW et al (2011) Clinical implications of the tumor volume reduction rate in head-and-neck cancer during definitive intensity-modulated radiotherapy for organ preservation. Int J Radiat Oncol Biol Phys 79:1096–1103CrossRefPubMed
27.
go back to reference Nam H, Park W, Huh SJ et al (2007) The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol 107:320–325CrossRefPubMed Nam H, Park W, Huh SJ et al (2007) The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol 107:320–325CrossRefPubMed
28.
go back to reference Mayr NA, Wang JZ, Lo SS et al (2010) Translating response during therapy into ultimate treatment outcome: a personalized 4-dimensional MRI tumor volumetric regression approach in cervical cancer. Int J Radiat Oncol Biol Phys 76:719–727CrossRefPubMed Mayr NA, Wang JZ, Lo SS et al (2010) Translating response during therapy into ultimate treatment outcome: a personalized 4-dimensional MRI tumor volumetric regression approach in cervical cancer. Int J Radiat Oncol Biol Phys 76:719–727CrossRefPubMed
29.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
30.
go back to reference Usmanij EA, de Geus-Oei LF, Troost EG et al (2013) 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med 54:1528–1534CrossRefPubMed Usmanij EA, de Geus-Oei LF, Troost EG et al (2013) 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med 54:1528–1534CrossRefPubMed
31.
go back to reference Van Baardwijk A, Bosmans G, Dekker A et al (2007) Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 82:145–152CrossRefPubMed Van Baardwijk A, Bosmans G, Dekker A et al (2007) Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 82:145–152CrossRefPubMed
32.
go back to reference Huang W, Fan M, Liu B et al (2014) Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med 55:1584–1590CrossRefPubMed Huang W, Fan M, Liu B et al (2014) Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med 55:1584–1590CrossRefPubMed
33.
go back to reference Machtay M, Duan F, Siegel BA et al (2013) Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol 31:3823–3830CrossRefPubMedPubMedCentral Machtay M, Duan F, Siegel BA et al (2013) Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol 31:3823–3830CrossRefPubMedPubMedCentral
34.
go back to reference Bral S, De Ridder M, Duchateau M et al (2011) Daily megavoltage computed tomography in lung cancer radiotherapy: correlation between volumetric changes and local outcome. Int J Radiat Oncol Biol Phys 80:1338–1342CrossRefPubMed Bral S, De Ridder M, Duchateau M et al (2011) Daily megavoltage computed tomography in lung cancer radiotherapy: correlation between volumetric changes and local outcome. Int J Radiat Oncol Biol Phys 80:1338–1342CrossRefPubMed
35.
go back to reference Fox J, Ford E, Redmond K et al (2009) Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 74:341–348CrossRefPubMed Fox J, Ford E, Redmond K et al (2009) Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 74:341–348CrossRefPubMed
Metadata
Title
Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy
Authors
Hiromitsu Kanzaki
Masaaki Kataoka
Atsushi Nishikawa
Kotaro Uwatsu
Kei Nagasaki
Noriko Nishijima
Takashi Ochi
Teruhito Mochizuki
Publication date
01-10-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 5/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-0982-0

Other articles of this Issue 5/2016

International Journal of Clinical Oncology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine